Shire plc

5 Riverwalk Citywest Business Campus,
Dublin, 24
Ireland,
+353 1 429 7700
www.shire.com

Shire plc is a global specialty biopharmaceutical company. Shire plc strive to develop best-in-class therapies across a core of rare disease areas including hematology, immunology, genetic diseases, neuroscience, and internal medicine with growing therapeutic areas in ophthalmics and oncology. Our diversified capabilities enable us to reach patients in more than 100 countries who are struggling to live their lives to the fullest.

M&A Summary

Buy vs Sell

Year ≤ '13 '14 '15 '16 '17 '18 T
Buy (1.6/yr) # 7 2 4 1 - 1 15
vol $5.6B $335M $11.5B $32.0B $49.4B
Sell (0.6/yr) # - 1 - 1 1 - 3
  18

Top M&A Advisors

Financial Deals
Sign-up to View
3
Sign-up to View
3
Sign-up to View
2
Legal Deals
Sign-up to View
4
Sign-up to View
2
Sign-up to View
2

Deal Values

Buy # TOTAL
> $1B Sign-up to View
$100M to $1B Sign-up to View
< $100M Sign-up to View
TOTAL Sign-up to View
Largest Baxalta, Inc.
$32.0B (2016-01-11)
Sell # Total
> $1B Sign-up to View
$100M to $1B Sign-up to View
< $100M Sign-up to View
Total Sign-up to View

Shire was acquired by Takeda Pharmaceutical on May 08, 2018.

Shire has acquired 15 companies of its own, including 8 in the last 5 years. A total of 2 acquisitions came from private equity firms. It has also divested 3 assets.

Shire’s largest acquisition to date was in 2016, when it acquired Baxalta for $32.0B. Shire has acquired in 7 different US states, and 4 countries. The Company’s most targeted sectors include life science (94%) and healthcare services (7%).

When analyzing the life science sector as a whole, according to Mergr, in the last 3 years, there are 407 life science companies that have made at least 1 acquisition, 14 have acquired at least 5 companies, and 2 have acquired more than 10 companies. The most prolific strategic life science acquirer over the past 3 years is Eurofins Scientific SA, with 30 acquisitions. The most prolific private equity acquirer in the life science sector over the past 3 years is Ampersand Capital Partners with 6 platform acquisitions.

Join Mergr and gain access to Shire’s M&A summary, the M&A summaries of companies just like it, as well as recent M&A activity in the life science sector.


What's Mergr?

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 3.5K Private Equity Firms
  • 123K M&A Transactions
  • 132K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 2.9K M&A Advisors
    (Investment Banks and Law Firms)
  • 35K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.